title: Methotrexate, mitoxantrone, 5-fluorouracil and leucovorin in metastatic breast cancer patients.
abstract: We have evaluated the efficacy and toxicity of a chemotherapy consisting of methotrexate, mitoxantrone, 5-Fluorouracil and leucovorin in 21 advanced breast cancer patients. Among 20 evaluable patients, objective response was obtained in 6 patients (30%) with two complete responses, stable disease in 4 patients (20%), while 10 patients (50%) progressed. Median progression-free survival and survival were 10 and 15 months, respectively. The most frequently observed side-effects were myelosuppression and emesis; one patient, who had previously received doxorubicin at the maximum dose-limiting cardiac toxicity, died of congestive heart failure after the third cycle. This treatment is moderately effective for advanced breast cancer patients.
authors.affiliation: Servizio di Oncologia Medica-E.O. Ospedali Galliera, Genova, Italy.
authors.forename: L
authors.initials: L
authors.lastname: Merlini
authors.forename: V
authors.initials: V
authors.lastname: Secondo
authors.forename: S
authors.initials: S
authors.lastname: Mammoliti
authors.forename: P
authors.initials: P
authors.lastname: Bellotti
authors.forename: C
authors.initials: C
authors.lastname: Castello
authors.forename: L
authors.initials: L
authors.lastname: Gallo
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D009362:Neoplasm Metastasis
chemical_list: D008942:Mitoxantrone; D002955:Leucovorin; D005472:Fluorouracil; D008727:Methotrexate